Kodiak Sciences Inc

KOD

$76M

Micro Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPALO ALTO123 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

4 upcoming, 1 past

⭐Phase 3Next

KSI-101 Phase 3 Results Expected

February 2026~KSI-101150

Primary completion for KSI-101 trial (NCT06990399) in Macular Edema Secondary to Inflammation

Source

⭐Phase 3

Tarcocimab tedromer Phase 3 Results Expected

August 2026~Tarcocimab tedromer675

Primary completion for Tarcocimab tedromer trial (NCT06556368) in Wet Age-related Macular Degeneration

Source

⭐Phase 3

Aflibercept Phase 3 Results Expected

August 2026~Aflibercept675

Primary completion for Aflibercept trial (NCT06556368) in Wet Age-related Macular Degeneration

Source

⭐Phase 3

KSI-101 Phase 3 Results Expected

December 2026~KSI-101150

Primary completion for KSI-101 trial (NCT06996080) in Macular Edema Secondary to Inflammation

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

KSI-101

Phase 3

Macular Edema Secondary to Inflammation

KSI-301

Phase 3

Macular Edema

Tarcocimab

Phase 3

Diabetic Retinopathy

Tarcocimab tedromer

Phase 3

Wet Age-related Macular Degeneration

Aflibercept

Phase 3

Wet Age-related Macular Degeneration

Drug Name	Phase	Indication	Designations
KSI-101	Phase 3	Macular Edema Secondary to Inflammation	-
KSI-301	Phase 3	Macular Edema	-
Tarcocimab	Phase 3	Diabetic Retinopathy	-
Tarcocimab tedromer	Phase 3	Wet Age-related Macular Degeneration	-
Aflibercept	Phase 3	Wet Age-related Macular Degeneration	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

KOD News